- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01343056
Program Reinforcement Impacts Self Management (PRISM) (PRISM)
Program Reinforcement Impacts Self Management
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Pennsylvania State University
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A person with diabetes referred for diabetes education
Exclusion Criteria:
- Gestational diabetes and pregnancy
- If a person has recently had diabetes education, they will not be enrolled in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Office Staff follow up education
A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up. The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment. |
The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
|
|
Active Comparator: Peer follow up education
A person with diabetes trained as a "peer" shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment.
|
Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
|
|
Active Comparator: Usual Care
ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education.
This one phone call will be made by the diabetes educator.
The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
|
Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
|
|
Active Comparator: Educator support follow up
A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment.
The diabetes educator uses behavioral goal setting as an education intervention.
The educator calls patient to determine goal attainment.
That is the intervention.
|
Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hemoglobin A1C (HbA1C, %)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Cholesterol (mg/dL)
Time Frame: 6 months
|
6 months
|
|
|
High Density Lipoprotein (HDL, mg/dL)
Time Frame: 6 months
|
6 months
|
|
|
Low Density Lipoprotein (LDL, mg/dL)
Time Frame: 6 months
|
6 months
|
|
|
Change in Diabetes Empowerment Scale- Short Form (DES-SF) Scores
Time Frame: 6 months
|
The DES-SF is a validated, 8 item scale that measures the self-efficacy of patients with diabetes. Responses are selected from a 5-point Likert scale (Strongly Disagree (1), Somewhat Disagree (2), Neutral (3), Somewhat Agree (4), Strongly Agree (5)). The scale is scored by averaging the scores of all completed items (sum of scores divided by 8). A positive number represents an improvement in overall patient self-efficacy (empowerment) from the baseline score and 6 month follow up time point. |
6 months
|
|
Body Mass Index
Time Frame: 6 months
|
Body Mass Index is a weight-to-height ratio, calculated by dividing one's weight in kilograms by the square of one's height in meters and used as an indicator of obesity and underweight.
|
6 months
|
|
Diastolic Blood Pressure
Time Frame: 6 months
|
Diastolic blood pressure is the pressure when the heart is at rest between beats.
|
6 months
|
|
Systolic Blood Pressure
Time Frame: 6 months
|
Systolic blood pressure is the pressure when the heart beats while pumping blood.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Linda Siminerio, RN, PhD, CDE, University of Pittsburgh
- Principal Investigator: Robert Gabbay, MD, PhD, Penn State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PRO10090392
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
State University of New York at BuffaloMedical University of South Carolina; National Institute of Diabetes and Digestive...CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
-
Leiden University Medical CenterAndaluz Health ServiceCompletedDiabetes Mellitus | Health Behavior | Self Efficacy | Type2 Diabetes Mellitus | Type1 Diabetes MellitusNetherlands, Spain
Clinical Trials on Office Staff Support
-
University Psychiatric Clinics BaselCompletedCompassion | Critical Incident | Social Climate | Staff Support | Workplace WellbeingSwitzerland
-
Virginia Ambulatory Care Outcomes Research NetworkCompleted
-
London School of Hygiene and Tropical MedicineStatens Serum InstitutCompletedMalaria | Hospital MortalityGuinea-Bissau
-
Assiut UniversityUnknown
-
Manchester Metropolitan UniversityThe Stroke Association, United KingdomCompletedPneumonia | Dysphagia | Acute StrokeUnited Kingdom
-
Cairo UniversityCompleted
-
University of NottinghamNottingham University Hospitals NHS TrustCompletedMental Health Wellness 1United Kingdom
-
Norwegian Institute of Public HealthThe National Institute of Occupational Health, NorwayRecruitingRespiratory Tract Infections | COVID-19Norway
-
Universidade Federal FluminenseActive, not recruitingTooth SensitivityBrazil
-
Istituto Ortopedico RizzoliRecruitingFunctional Recovery | Reliability | Joint ReplacementItaly